Tagged with LatAm

Mexico Monica Palomanes, General Manager of Roche Mexico, discusses her journey within the company and the shift from traditional sales to a collaborative approach with Patient Journey Partners. She addresses challenges in access and diagnosis within Mexico’s fragmented healthcare system, while recognising the country’s potential for clinical research due to the…

Puerto Rico With lower labour costs than mainland US, but the same regulatory framework and straightforward market access, Puerto Rico has long presented a compelling value proposition for pharmaceutical manufacturing, a sector that accounts for some 30 percent of the island’s GDP.  After bouncing back from bankruptcy, devastating hurricanes and the COVID-19…

Mexico Sworn in this month as Mexico’s first female president, Claudia Sheinbaum has pledged “continuity with change,” with respect to her predecessor Andrés Manuel López Obrador’s policies. While she has promised to drive forward the healthcare reforms López Obrador introduced – namely universal coverage – she has also set out a…

Mexico Carlos Salazar, president of the National Association of Healthcare Providers (ANAPS) and director general of the association’s medical device trade event, Medical Expo, discusses ANAPS’ role in supporting the medical device industry in Mexico, the stellar growth of the sector, and the influx of foreign investment and the opportunities presented…

Mexico Arturo Rodriguez, CEO of Infinite Clinical Research, discusses the current state of clinical trials in Mexico and highlights the country’s unique advantages, such as a diverse population with experienced medical professionals and top-notch medical facilities. He addresses the challenges of streamlining regulatory processes and the need for improvements to attract…

Mexico Organon’s recently-appointed LAMEX Cluster Head Julio Conejero lays out how Organon is committed to improving women’s health and addressing unmet needs through its portfolio. This mission aligns with the rise of female leadership in Latin America and the broader movement towards women’s empowerment. Now based in Mexico – which accounts…

LatAm An overview of some of the biggest news from Latin American pharma, including Onconic Therapeutics’ licensing deal with Laboratorios Sanfer for 19 LatAm countries; Lupin’s orphan drug partnership with Argentina’s Celnova Pharma; Grifols’ distribution deal with Gema Biotech; the downturn in Uruguay’s medicinal canibis industry, and Novartis’ increased clinical trial…

Mexico The French Chamber of Commerce in Mexico (CCI France Mexico) has been helping French companies such as Sanofi, Servier and Pierre Fabre establish themselves in Mexico for 140 years. General manager Hajer Najjar outlines how the CCI supports French investment in Mexico and promotes Mexican exports to France, and reviews…

Mexico Jorge Luis Caridad, managing director of Johnson & Johnson Innovative Medicine, Mexico, explores his 18-year journey within the company, emphasizing his alignment with J&J’s values and its mission to transform global health. Caridad discusses the challenges and opportunities presented by the Mexican market, the company’s commitment to advancing innovation in…

Mexico Founded in 1943, Mexican drugmaker Silanes has built a strong presence across multiple therapeutic areas, namely diabetes and cardiovascular, while expanding into others. The company’s director of pharma and biologics, Rafael Quintanilla, explains Silanes’ journey from being purely a branded generics manufacturer to embracing R&D, which has brought substantial growth…

Mexico Francisco Chavez from Thermo Fisher Scientific explains the company’s global mission to advance science and healthcare, with a particular focus on Latin America. Chavez highlights Thermo Fisher’s significant investment in R&D and its strategic approach to addressing regional healthcare challenges through public-private partnerships.   Our commitment is to create a…

Mexico David López García, a pharma industry executive and rare disease expert, discusses the challenges and advancements in treating rare diseases in Mexico. He highlights the importance of public-private partnerships and the growing interest from industry in the rare disease field.   Every day is an opportunity to make a difference…